Medicus Pharma has filed a registration study with the FDA for its SkinJect treatment aimed at Gorlin syndrome, a rare disorder causing multiple basal cell lesions. This step could lead to commercialization if positive results support a New Drug Application. The company has also applied for orphan drug and pediatric rare disease designations, which offer regulatory and financial benefits. Additionally, Medicus Pharma secured over $22 million from an institutional investor, boosting its cash to about $30 million to fund operations for over two years.
Hyperliquid's weekly revenue surpassed $20.22 million in early June 2026, breaking a multi-month consolidation phase where revenue ranged between $8 million and $15 million. This rebound reflects renewed momentum in derivatives trading, particularly ...
Fidelity is steering away from bonds issued by major tech companies like Amazon, Alphabet, Meta, Microsoft, and Oracle, which are raising hundreds of billions to fund AI infrastructure. Despite strong credit ratings, these bonds offer minimal yield p...
Strategy Bitcoin treasury evolved from a cautious approach of allocating only 5-10% of the balance sheet to Bitcoin, as initially preferred by CEO Phong Le, to a full balance sheet Bitcoin exposure advocated by Michael Saylor. Over time, Phong Le ack...
PayPal's PYUSD stablecoin supply has decreased by 31%, falling from a $4.2 billion peak in March 2026 to about $2.92 billion. This $1 billion reduction reflects changing liquidity flows, reduced minting, and cautious market participation amid broader...
Ethereum's market capitalization has fallen to about $186.263 billion, while Tether's stablecoin market cap rose to approximately $187.05 billion, marking a rare flip where Tether overtakes Ethereum. This shift is driven by increased demand for stabl...
